Cargando…

Ellagic acid-Fe@BSA nanoparticles for endogenous H(2)S accelerated Fe(III)/Fe(II) conversion and photothermal synergistically enhanced chemodynamic therapy

Rationale: Chemodynamic therapy (CDT) based on the Fe(II)-mediated Fenton reaction is an emerging tumor treatment strategy. However, the catalytic efficiency in tumors is crucially limited by Fe(II). Herein, an endogenous hydrogen sulfide (H(2)S) accelerated Fe(III)/Fe(II) transformation and phototh...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Qingqing, An, Lu, Tian, Qiwei, Lin, Jiaomin, Yang, Shiping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086347/
https://www.ncbi.nlm.nih.gov/pubmed/32226542
http://dx.doi.org/10.7150/thno.41882
_version_ 1783509108384595968
author Tian, Qingqing
An, Lu
Tian, Qiwei
Lin, Jiaomin
Yang, Shiping
author_facet Tian, Qingqing
An, Lu
Tian, Qiwei
Lin, Jiaomin
Yang, Shiping
author_sort Tian, Qingqing
collection PubMed
description Rationale: Chemodynamic therapy (CDT) based on the Fe(II)-mediated Fenton reaction is an emerging tumor treatment strategy. However, the catalytic efficiency in tumors is crucially limited by Fe(II). Herein, an endogenous hydrogen sulfide (H(2)S) accelerated Fe(III)/Fe(II) transformation and photothermal synergistically enhanced CDT strategy based on ellagic acid-Fe-bovine serum albumin (EA-Fe@BSA) nanoparticles (NPs) was developed for colon tumor inhibition. On the one hand, the Fe(III) with low catalytic activity in the EA-Fe@BSA NPs could be rapidly reduced to the highly active Fe(II) by the abundant H(2)S in colon cancer tissues. Thus, a rapid Fe(III)/Fe(II) conversion system was established, wherein highly active Fe(II) ions were continuously regenerated to improve the CDT efficiency. On the other hand, the photothermal effect of EA-Fe@BSA NPs also accelerated the production of hydroxyl radicals (•OH), thereby synergistically enhancing the CDT performance and improving the therapeutic efficacy. Methods: The endogenous H(2)S accelerated Fe(III)/Fe(II) conversion and PTT enhanced CDT were investigated by characterization of the Fe valence state and detection of •OH. T(1)-weighted magnetic resonance imaging (MRI) was tested both in vitro and in vivo. The biocompatibility of NPs were examined via MTT assay, hemolysis analysis and routine blood measurements. The enhanced CDT was investigated in HCT116 colon cancer cells by Calcein-AM/PI staining and MTT assay, and tumor inhibition was demonstrated in HCT116 tumor bearing mice. Results: In this work, EA-Fe@BSA NPs were constructed as a CDT theranostic reagent. The H(2)S accelerated Fe(III)/Fe(II) conversion was confirmed, more degradation of MB and generation of •OH demonstrated the enhanced CDT in vitro. EA-Fe@BSA NPs exhibited good T(1)-weighted MRI performance. More importantly, it displayed strong near-infrared (NIR) absorption and excellent photothermal efficiency, further promotes the production of •OH. Hence, the efficacy of CDT was enhanced, and the tumor growth was inhibited efficiently. Conclusion: All results demonstrate that this strategy based on endogenous H(2)S promoted Fe(III)/Fe(II) transformation together with PTT acceleration permits efficient Fenton-reaction- mediated CDT both in vitro and in vivo, which holds great potential for effective colon cancer theranostics.
format Online
Article
Text
id pubmed-7086347
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-70863472020-03-27 Ellagic acid-Fe@BSA nanoparticles for endogenous H(2)S accelerated Fe(III)/Fe(II) conversion and photothermal synergistically enhanced chemodynamic therapy Tian, Qingqing An, Lu Tian, Qiwei Lin, Jiaomin Yang, Shiping Theranostics Research Paper Rationale: Chemodynamic therapy (CDT) based on the Fe(II)-mediated Fenton reaction is an emerging tumor treatment strategy. However, the catalytic efficiency in tumors is crucially limited by Fe(II). Herein, an endogenous hydrogen sulfide (H(2)S) accelerated Fe(III)/Fe(II) transformation and photothermal synergistically enhanced CDT strategy based on ellagic acid-Fe-bovine serum albumin (EA-Fe@BSA) nanoparticles (NPs) was developed for colon tumor inhibition. On the one hand, the Fe(III) with low catalytic activity in the EA-Fe@BSA NPs could be rapidly reduced to the highly active Fe(II) by the abundant H(2)S in colon cancer tissues. Thus, a rapid Fe(III)/Fe(II) conversion system was established, wherein highly active Fe(II) ions were continuously regenerated to improve the CDT efficiency. On the other hand, the photothermal effect of EA-Fe@BSA NPs also accelerated the production of hydroxyl radicals (•OH), thereby synergistically enhancing the CDT performance and improving the therapeutic efficacy. Methods: The endogenous H(2)S accelerated Fe(III)/Fe(II) conversion and PTT enhanced CDT were investigated by characterization of the Fe valence state and detection of •OH. T(1)-weighted magnetic resonance imaging (MRI) was tested both in vitro and in vivo. The biocompatibility of NPs were examined via MTT assay, hemolysis analysis and routine blood measurements. The enhanced CDT was investigated in HCT116 colon cancer cells by Calcein-AM/PI staining and MTT assay, and tumor inhibition was demonstrated in HCT116 tumor bearing mice. Results: In this work, EA-Fe@BSA NPs were constructed as a CDT theranostic reagent. The H(2)S accelerated Fe(III)/Fe(II) conversion was confirmed, more degradation of MB and generation of •OH demonstrated the enhanced CDT in vitro. EA-Fe@BSA NPs exhibited good T(1)-weighted MRI performance. More importantly, it displayed strong near-infrared (NIR) absorption and excellent photothermal efficiency, further promotes the production of •OH. Hence, the efficacy of CDT was enhanced, and the tumor growth was inhibited efficiently. Conclusion: All results demonstrate that this strategy based on endogenous H(2)S promoted Fe(III)/Fe(II) transformation together with PTT acceleration permits efficient Fenton-reaction- mediated CDT both in vitro and in vivo, which holds great potential for effective colon cancer theranostics. Ivyspring International Publisher 2020-03-04 /pmc/articles/PMC7086347/ /pubmed/32226542 http://dx.doi.org/10.7150/thno.41882 Text en © The author(s) This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Research Paper
Tian, Qingqing
An, Lu
Tian, Qiwei
Lin, Jiaomin
Yang, Shiping
Ellagic acid-Fe@BSA nanoparticles for endogenous H(2)S accelerated Fe(III)/Fe(II) conversion and photothermal synergistically enhanced chemodynamic therapy
title Ellagic acid-Fe@BSA nanoparticles for endogenous H(2)S accelerated Fe(III)/Fe(II) conversion and photothermal synergistically enhanced chemodynamic therapy
title_full Ellagic acid-Fe@BSA nanoparticles for endogenous H(2)S accelerated Fe(III)/Fe(II) conversion and photothermal synergistically enhanced chemodynamic therapy
title_fullStr Ellagic acid-Fe@BSA nanoparticles for endogenous H(2)S accelerated Fe(III)/Fe(II) conversion and photothermal synergistically enhanced chemodynamic therapy
title_full_unstemmed Ellagic acid-Fe@BSA nanoparticles for endogenous H(2)S accelerated Fe(III)/Fe(II) conversion and photothermal synergistically enhanced chemodynamic therapy
title_short Ellagic acid-Fe@BSA nanoparticles for endogenous H(2)S accelerated Fe(III)/Fe(II) conversion and photothermal synergistically enhanced chemodynamic therapy
title_sort ellagic acid-fe@bsa nanoparticles for endogenous h(2)s accelerated fe(iii)/fe(ii) conversion and photothermal synergistically enhanced chemodynamic therapy
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7086347/
https://www.ncbi.nlm.nih.gov/pubmed/32226542
http://dx.doi.org/10.7150/thno.41882
work_keys_str_mv AT tianqingqing ellagicacidfebsananoparticlesforendogenoush2sacceleratedfeiiifeiiconversionandphotothermalsynergisticallyenhancedchemodynamictherapy
AT anlu ellagicacidfebsananoparticlesforendogenoush2sacceleratedfeiiifeiiconversionandphotothermalsynergisticallyenhancedchemodynamictherapy
AT tianqiwei ellagicacidfebsananoparticlesforendogenoush2sacceleratedfeiiifeiiconversionandphotothermalsynergisticallyenhancedchemodynamictherapy
AT linjiaomin ellagicacidfebsananoparticlesforendogenoush2sacceleratedfeiiifeiiconversionandphotothermalsynergisticallyenhancedchemodynamictherapy
AT yangshiping ellagicacidfebsananoparticlesforendogenoush2sacceleratedfeiiifeiiconversionandphotothermalsynergisticallyenhancedchemodynamictherapy